Chikungunya — viral disease transmitted by Aedes mosquitoes

Symptoms and clinical course

Typical early features include fever, symmetric polyarthralgia (often of hands, wrists, knees, and ankles), rash, and fatigue. Other manifestations may include headache, muscle pain and conjunctivitis. Joint pain can be debilitating and may last months to years in a minority of patients. For symptom checklists and clinical descriptions see clinical information and disease details.

Transmission and vectors

The virus is transmitted to humans primarily by two mosquito species: Aedes albopictus and Aedes aegypti. These mosquitoes become infected by feeding on viremic hosts and then spread the virus through subsequent bites. Nonhuman hosts such as monkeys, birds, cattle, and rodents can participate in local transmission cycles in some regions; see ecological notes at reservoirs and risk.

Diagnosis and differential

Diagnosis is made by clinical assessment supported by laboratory testing (PCR in early infection, serology later). Chikungunya can resemble dengue, Zika and other febrile illnesses, so laboratory confirmation is important where multiple arboviruses circulate. Practical diagnostic guidance is available at diagnostic guidance and laboratory methods.

Treatment, prevention and control

There is no specific antiviral therapy approved for chikungunya; management focuses on supportive care — pain control, hydration, and monitoring for complications. Aspirin is generally avoided in acute febrile illness until dengue is excluded. Preventive efforts center on vector control, personal protection (repellents, clothing, screens), and community measures to reduce mosquito breeding. Public‑health resources and control strategies are summarized at control strategies and outbreak response.

History, outbreaks and epidemiology

Known since the mid‑20th century, chikungunya reemerged with major outbreaks after 2004 and has affected parts of Asia, Europe and the Americas. Attack rates in outbreaks can be high where susceptible populations and competent vectors coexist. Mortality is relatively low — reported estimates suggest about one in a thousand infections may be fatal in some series — but the disease burden is substantial because of intense short‑term illness and possible chronic joint disability; see mortality and burden discussions at overview and vector notes.

Notable facts and ongoing research

Research continues on vaccines, antiviral agents, and improved vector control methods. Surveillance and rapid laboratory confirmation are important when chikungunya co‑circulates with other arboviruses. For research summaries and public health resources consult surveillance, vaccine research, therapeutic research, and operational guidance at health authority pages.

• Key prevention points: mosquito bite avoidance, source reduction, and rapid case detection — see prevention.
• When to seek care: high fevers, severe pain, bleeding, or worsening condition in older adults — clinical advice at care guidance.